Gold bars to be exempt from tariffs, White House clarifies
Investing.com - H.C. Wainwright has reiterated a Buy rating and $27.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), representing a 74% upside from the current price of $15.51, following the FDA approval of its hereditary angioedema (HAE) treatment Ekterly. The company, with a market capitalization of $771 million, has seen its stock surge nearly 98% over the past six months.
The research firm highlighted the favorable aspects of Ekterly’s label, noting it contains no listed contraindications and includes approval for the higher 600 mg dose for both adults and adolescents.
In the Phase 3 KONFIDENT trial, both the 300 mg and 600 mg doses demonstrated significantly faster symptom relief compared to placebo, with median times to relief of 1.61 hours and 1.79 hours respectively, versus 6.72 hours for placebo.
The label lists only headache as a treatment-related adverse event and permits patients to take a second dose three hours after the first, which H.C. Wainwright views as reinforcing the drug’s safety profile.
The approved label places no restrictions based on attack location or severity and allows use in patients receiving prophylactic therapy, which H.C. Wainwright believes positions Ekterly to potentially reach the full spectrum of HAE patients in the U.S.
In other recent news, Kalvista Pharmaceuticals Inc has announced the U.S. launch of Ekterly, an FDA-approved oral treatment for hereditary angioedema (HAE) attacks. The drug is priced at $16,720 per dose, and Leerink Partners has maintained an Outperform rating with a price target of $20.00, projecting U.S. sales of $34.0 million for fiscal year 2026. JMP Securities has also raised its price target for Kalvista to $27.00, citing higher expected peak sales for Ekterly. BofA Securities increased its price target to $37.00, highlighting Ekterly’s unique position as the only oral on-demand treatment in the HAE market. Stifel reiterated a Buy rating with a price target of $39.00, noting the favorable label and potential for market adoption. Kalvista is preparing for international launches, with EMA decisions and targeted launches in Germany, Japan, and the United Kingdom (TADAWUL:4280) expected in the coming years. The company has also established commercialization agreements with Kaken Pharmaceutical (TADAWUL:2070) for Japan and Pendopharm for Canada. Analysts from various firms have expressed optimism about Ekterly’s market potential, emphasizing its unique offering in the HAE treatment landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.